Together these data show that the three CDK4/6 inhibitors palbociclib, abemaciclib and ribociclib are capable of reducing proliferation and inducing differentiation of the neuroblastoma cell line SK-N-BE(2)Cin vitro, without extensive cell death. The gene discussed is CDK4; the disease is neuroblastoma.